ADHD

The results also show a bigger increase among adults between 2012-2017, which could be due to increased sensitivity of diagnosis.

Overall, 30.60% of pediatric patients who presented to the emergency department with mild head trauma were diagnosed with ADHD, compared to 8.96% of the control group.

ADHD and ODD dimensions were associated differently with different types of impulsivity, with unique patterns of network connectivity.

The results show pediatric patients with ADHD had a significantly higher risk of injuries requiring hospitalization compared to non-ADHD controls.

Older participants had smaller dual-task performance deficits for gait and texting speed in both the ADHD group and the control group.

Multivariate dimensional association scores resulted in an overall increase and normalization with age in the ADHD.

Prefrontal anodal transcranial direct current stimulation is more effective in treating ADHD compared to stimulation of the right inferior frontal gyrus.

The relative contribution of genetic influences to psychotic experiences was lower with increasing environmental exposure for paranoia, cognitive disorganization, grandiosity, and anhedonia.

Patients with dementias also had higher levels of NA-OXS, as did psychotic and bipolar disorders.

Mean inattention scores were about 5 points lower in the tDCS group compared to the sham treatment group.

The prevalence of suicidal was 10.9% in studies that included child-reported outcomes for child only and 10.4% for child and parent combined.

The patients prescribed stimulants were more likely to not have coexisting conditions than those treated with A2A.

Patients with autism had a fivefold increase in adjusted relative risk of self-harm.

The approval expands the indication for Qelbree to all patients with ADHD aged 6 years and older, and provides adult patients their first novel non-stimulant option in 20 years.

Birgit H. Amann, MD; Rakesh Jain, MD, MPH; Theresa R. Cerulli, MD; and David W. Goodman, MD, share unmet needs and risks in the treatment of adult ADHD.

Dr David W. Goodman reviews the efficacy and tolerability of different classes of medications for the management of ADHD.

Rakesh Jain, MD, MPH, explores the role of an integrative treatment approach in regard to nonpharmacological treatment for the management of adult ADHD.

Rakesh Jain, MD, MPH, leads a discussion on factors that guide treatment selection for adult patients with ADHD.

The digital software program was significantly beneficial and tolerable among patients who used it over 6 weeks, according to new findings.

Experts in ADHD discuss the benefits and challenges of telehealth on the diagnosis and management of adult ADHD.

Birgit H. Amann, MD, and Greg Mattingly, MD, review patient and provider goals of treatment and provide insight on evaluating response to treatment for ADHD.

Greg Mattingly, MD; David W. Goodman, MD; Birgit H. Amann, MD; and Theresa R. Cerulli, MD, evaluate the role of pediatric ADHD guidelines and common misconceptions in the diagnosis and treatment of ADHD.

Drs Birgit H. Amann, David W. Goodman, and Greg Mattingly discuss signs and symptoms that may prompt testing for adult ADHD and share their considerations for approaching diagnosis.

Experts in the management of ADHD comment on unmet needs in disease management in the areas of diagnosis, treatment, and coverage of symptoms.

Birgit H. Amann, MD; Rakesh Jain, MD, MPH; David W. Goodman, MD; Greg Mattingly, MD; and Theresa R. Cerulli, MD, share insight on the impact of ADHD on quality of life in adult patients.